Biohaven Ltd. Common Shares

IPO

Clinical-stage Biopharmaceutical Company | Biohaven

healthtech

biotech

Headquarters: New Haven, Connecticut
Employees: 201–500
Founded: 2013
Business Model: B2B
Website: biohaven.com

Total Funding: $493.6M
Last Round: $375.0M Venture RoundAug 2020
Rounds: 4
Type: Public

About

Biohaven is a clinical-stage biopharmaceutical company advancing a portfolio of more than 10 drug candidates across 6 therapeutic areas including neurology, immunology, oncology, and cardiometabolic disease. Its proprietary platforms — MoDE extracellular protein degraders, Kv7 potassium channel activators, and myostatin inhibitors — target rare and common diseases with unmet needs. Lead programs include BHV-8000 for Parkinson's disease and Alzheimer's, opakalim (BHV-7000) for epilepsy, and taldefgrobep alfa for spinal muscular atrophy and obesity.

LinkedIn X (Twitter)

Tech & App Stack

Tech & App Stack is available on paid plans

Upgrade to Silver or higher to reveal the full technology and app stack for any company.

View pricing

Sign up to view funding chart

Create a free account to see funding visualizations and detailed round data.

Create Free Account

Funding History

Secondary Market

Biohaven Ltd. Common Shares

About

Tech & App Stack

Sign up to view funding chart

Funding History

Investors

Sign up to view investors

Similar Companies